Bulletin from the Annual General Meeting 2025

The Annual General Meeting 2025 of RaySearch Laboratories AB (publ) was held on May 22, 2025, in Stockholm, Sweden. The following resolutions were adopted.

STOCKHOLM, May 22, 2025 /PRNewswire/ -- It was resolved to re-elect Carl Filip Bergendal, Johan Löf, Günther Mårder, Britta Wallgren and Hans Wigzell as Board members of the company and to re-elect Hans Wigzell as Chairman of the Board.

The Annual General Meeting adopted the balance sheets and income statements and discharged the members of the Board and the CEO from liability. It was resolved, in accordance with the Board's proposal, on a dividend of SEK 3 per share and that the remaining accumulated profit, amounting to SEK 187,755,281 be brought forward and balanced in the new accounts. The record date for the dividend was determined to be May 26, 2025.

It was resolved that remuneration to Board members who do not receive a salary from any Group company, shall amount to SEK 840,000 to the Chairman of the Board and SEK 300,000 to each of the other Board members elected by the general meeting.

It was resolved, in accordance with the Board's proposal, to re-elect the auditing firm Deloitte AB as auditor for the period until the next Annual General Meeting. Further, it was resolved that the auditor's fees be paid in accordance with approved invoicing.

The Annual General Meeting also resolved to approve the Board's remuneration report for 2024 and to adopt the Board's proposal for guidelines on executive remuneration.

More information and complete documentation relating to the Annual General Meeting is available at www.raysearchlabs.com.

About RaySearch

RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems. 

RaySearch's software has been sold to over 1,100 clinics in 47 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.

* Subject to regulatory clearance in some markets.

For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: + 46 (0) 8 510 530 00
[email protected]

Nina Grönberg, CFO, RaySearch Laboratories AB (publ)
Telephone: + 46 (0) 8 510 530 00
[email protected]

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/raysearch-laboratories/r/bulletin-from-the-annual-general-meeting-2025,c4154251

The following files are available for download:

View original content:https://www.prnewswire.com/news-releases/bulletin-from-the-annual-general-meeting-2025-302463658.html

SOURCE RaySearch Laboratories